Did You Know...
...During the Civil War, the Confederacy established its own Patent Office which issued 266 patents, a third of which concerned implements of war.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Application No. | Application Title | Issue Date |
| 20120034267 | INACTIVATED VARICELLA ZOSTER VIRUS VACCINES, METHODS OF PRODUCTION, AND USES THEREOF The invention provides an inactivated varicella zoster virus (VZV), and compositions and vaccines comprising said inactivated VZV, wherein the infectivity of the VZV is undetectable and wherein the inactivated VZV induces an immune response against VZV when administered... | 02/09/2012 |
| 20120020998 | PLASMACYTOID DENDRITIC CELL LINE USED IN ACTIVE OR ADOPTIVE CELL THERAPY The present invention relates to a method for inducing and amplifying specific effectors, which comprises obtaining pulsed plasmacytoid dendritic cells (pDC) by incubation of a pDC line with at least one antigen, the pulsed pDC being subsequently irradiated and brought ... | 01/26/2012 |
| 20120014989 | PYRROLO[2,3-b]PYRIDIN-4-YL-AMINES AND PYRROLO[2,3-b]PYRIMIDIN-5-YL-AMINES AS JANUS KINASE INHIBITORS The present invention provides pyrrolo[2,3-b]pyridine-4-yl amines pyrrolo[2,3-b]pyrimidin-4-yl amines that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related dise... | 01/19/2012 |
| 20120003277 | NANOEMULSION VACCINES The present invention provides methods and compositions for the stimulation of immune responses. Specifically, the present invention provides nanoemulsion compositions harboring one or more immunogens within the oil phase of the nanoemulsion and methods of using the sam... | 01/05/2012 |
| 20110293723 | SYNTHETIC NANOCARRIER COMBINATION VACCINES Disclosed are dosage forms and related methods, that include a first population of synthetic nanocarriers that have one or more first antigens coupled to them, one or more second antigens that are not coupled to the synthetic nanocarriers, and a pharmaceutically accepta... | 12/01/2011 |
| 20110200633 | Cytomegalovirus Surface Protein Complex for Use in Vaccines and as a Drug Target Immunogenic compositions and prophylactic or therapeutic vaccines for use in protecting and treating against human cytomegalovirus (CMV) are disclosed. Subunit vaccines comprising a human CMV protein complex comprising pUL128 or pUL130, and nucleic acid vaccines compris... | 08/18/2011 |
| 20110189233 | Recombinant Varicella-Zoster Virus A recombinant varicella-zoster virus; a process for producing the same; a pharmacological composition containing recombinant varicella-zoster virus; a vector containing a genomic gene of varicella-zoster virus and BAC vector sequence; cells containing the above vector; ... | 08/04/2011 |
| 20110182847 | USE OF TLR AGONISTS AND/OR TYPE 1 INTERFERONS TO ALLEVIATE TOXICITY OF TNF-R AGONIST THERAPEUTIC REGIMENS Improved (safer and more effective) methods of therapy using TNF-R agonists, e.g., CD40 agonists are provided. These methods provide for the addition of an amount of a type 1 interferon and/or a TLR agonist that is effective to prevent or reduce the toxicity (liver toxi... | 07/28/2011 |
| 20110177124 | CODON-OPTIMIZED POLYNUCLEOTIDE-BASED VACCINES AGAINST HUMAN CYTOMEGALOVIRUS INFECTION The invention is related to polynucleotide-based cytomegalovirus vaccines. In particular, the invention is plasmids operably encoding HCMV antigens, in which the naturally-occurring coding regions for the HCMV antigens have been modified for improved translation in huma... | 07/21/2011 |
| 20110135679 | COMPOSITIONS FOR INDUCING IMMUNE RESPONSES The invention provides, inter alia, immunogenic compositions that comprise (a) a first antigen, (b) at least first and second adjuvants, wherein the first adjuvant comprises microparticles and wherein the second adjuvant comprises an imidazoquinoline compound, and (c) a... | 06/09/2011 |
| 20110110979 | METHOD AND VACCINE FOR OPTIMIZING THE SPECIFIC IMMUNE RESPONSES The present invention relates to a method for treating an infection or disease or lesion, in particular an HPV infection. Furthermore, it relates to a vaccine for treating a Human Papillomavirus (HPV) infection or an associated disease or lesion in a subject.... | 05/12/2011 |
| 20110104260 | VACCINE AGAINST VARICELLA ZOSTER VIRUS Use of an immunogenic composition comprising VZV gE, or immunogenic fragment thereof, and a TH-1 adjuvant in the preparation of a medicament for the prevention or amelioration of shingles and/or post herpetic neuralgia. Compositions comprising a truncated VZV gE antigen... | 05/05/2011 |
| 20110086065 | Lentival Vector-Based Vaccine Methods of eliciting humoral responses, methods of immunization, and methods of vaccination using lentiviral vector are disclosed. Additionally, immunogenic compositions and vaccines for West Nile Virus are disclosed.... | 04/14/2011 |
| 20110064768 | Immunogenic Compositions An immunogenic composition comprising a viral vector, said vector comprising a nucleic acid sequence encoding a C4bp domain or variant or fragment thereof and a nucleic acid sequence encoding an antigen of interest.... | 03/17/2011 |
| 20110059133 | EX VIVO METHOD FOR PRODUCING A PREPARATION CONTAINING CD4+ T CELLS SPECIFIC FOR EBV STRUCTURAL ANTIGENS The present invention discloses an ex vivo method for producing a preparation containing CD4+ T cells specific for EBV structural antigens for use in the prophylaxis and treatment of patients with a reduced T cell activity in order to prevent or treat growth of EBV infe... | 03/10/2011 |
| 20110045059 | VACCINE AGAINST VARICELLA ZOSTER VIRUS Use of an immunogenic composition comprising VZV gE, or immunogenic fragment thereof, and a TH-1 adjuvant in the preparation of a medicament for the prevention or amelioration of shingles and/or post herpetic neuralgia. Compositions comprising a truncated VZV gE antigen... | 02/24/2011 |
| 20110033499 | ANTI-VIRAL NUTRACEUTICAL A method for the prophylaxis or treatment of a viral infection in a mammal is described. The method comprises administering to the mammal an effective amount of a mollusc hemocyanin and/or an active fragment thereof. The hemocyanin may be an abalone hemocyanin.... | 02/10/2011 |
| 20110008387 | COMPOSITION CONTAINING HCMV PARTICLES The present invention is related to a composition comprising an agent selected from the group comprising HCMV virions, HCMV dense bodies and HCMV NIEP, whereby the composition is capable of elucidating an immune response while the virions, the NIEP and/or the dense bodi... | 01/13/2011 |
| 20100285135 | Nanoparticles For Use In Immunogenic Compositions Disclosed herein are sterile-filtered lyophilized nanoparticle compositions which contain at least one biodegradable polymer, at least one surfactant, at least one cryoprotective agent and at least one antigen. Also disclosed are methods of making and using such composi... | 11/11/2010 |
| 20100285060 | ALPHA THYMOSIN PEPTIDES AS VACCINE ENHANCERS The present invention provides methods of vaccination as well as pharmaceutical combinations and kits for enhancing vaccine effectiveness, including for immunodeficient or immunecompromised patients, including non-responders and low-responders to vaccination. As disclos... | 11/11/2010 |
| 20100272752 | VACCINE FOR VIRUSES THAT CAUSE PERSISTENT OR LATENT INFECTIONS The invention is in general directed to methods and compositions for preventing or treating infections by viruses involved in persistent and/or latent infections. The methods and compositions are directed toward the prevention and treatment of infections caused by virus... | 10/28/2010 |
| 20100247537 | ADJUVANT COMBINATIONS OF NKT ACTIVATOR, CD40 AGONIST, AND OPTIONAL ANTIGEN, THE USE THROUGH INDUCING SYNERGISTIC CELLULAR IMMUNITY Adjuvant combinations comprising at least one NKT activator, such as alpha-galactosylceramide (α-Gal-Cer) or iGb3, a CD40 agonist and optionally an antigen are disclosed. The use of these immune adjuvants for treatment of various chronic diseases such as cancers is als... | 09/30/2010 |
| 20100239608 | PHARMACEUTICAL COMPOSITION CONTAINING A STABILISED mRNA OPTIMISED FOR TRANSLATION IN ITS CODING REGIONS The present invention relates to a pharmaceutical composition containing an mRNA that is stabilised by sequence modifications in the translated region and is optimised for the translation. The pharmaceutical composition according to the invention is particularly suitabl... | 09/23/2010 |
| 20100136043 | COMPOSITION COMPRISING IMMUNOGENIC MICROPARTICLES The invention provides an immunogenic composition comprising at least one antigen in association with micropar-tides, wherein the microparticles are in the same size range as viruses. In addition the invention also provides vaccine compositions and methods of eliciting ... | 06/03/2010 |
| 20100068229 | RECOMBINANT ANTIGENS OF HUMAN CYTOMEGALOVIRUS (HCMV) The invention described herein relates to a method for identifying the antigenic regions of HCMV proteins involved in the human B-cell response to HCMV infection, for combining such antigenic regions in the form of chimeric fusion products, and their use as diagnostic a... | 03/18/2010 |
| 20100055129 | MODULATORS OF MYC, METHODS OF USING THE SAME, AND METHODS OF INDENTIFIYING AGENTS THAT MODULATE MYC Disclosed herein are methods of modulation of the viability of a cell. Further disclosed herein are methods of modulating an immune response. Further disclosed herein are methods of identifying agents capable of modulation of the viability of a cell or an immune respons... | 03/04/2010 |
| 20100047277 | VIROSOMES, METHODS OF PREPARATION, AND IMMUNOGENIC COMPOSITIONS Briefly described, virosomes, methods of preparing virosomes, immunogenic compositions that include virosomes, and methods of eliciting an immune response using immunogenic compositions that include virosomes are described herein. A virosome can include at least one vir... | 02/25/2010 |
| 20100028382 | Lentival Vector-Based Vaccine Methods of eliciting humoral responses, methods of immunization, and methods of vaccination using lentiviral vector are disclosed. Additionally, immunogenic compositions and vaccines for West Nile Virus are disclosed.... | 02/04/2010 |
| 20090285851 | VACCINE COMPRISING MONOCYTE OR IMMATURE MYELOID CELLS (IMC) WHICH WERE LOADED WITH THE LIGAND OF NATURAL KILLER T CELL AND ANTIGEN The present invention relates to an immuno-therapeutic and prophylactic vaccine comprising monocytes or immature myeloid cells (IMCs) loaded with the ligand of natural killer T cell and an antigen for the prevention and treatment of infectious disease or cancer, more pr... | 11/19/2009 |
| 20090280142 | METHODS OF DIAGNOSIS AND TREATMENT OF OSTEOPOROSIS A method of detecting osteoporosis in a mammalian is disclosed herein which includes:
| 11/12/2009 |
| 20090123367 | Soluble Glycosaminoglycanases and Methods of Preparing and Using Soluble Glycosaminoglycanases The invention relates to the discovery of novel soluble neutral active Hyaluronidase Glycoproteins (sHASEGPs), methods of manufacture, and their use to facilitate administration of other molecules or to alleviate glycosaminoglycan associated pathologies. Minimally activ... | 05/14/2009 |
| 20090081230 | HUMAN CYTOMEGALOVIRUS NEUTRALISING ANTIBODIES AND USE THEREOF The invention relates to neutralizing antibodies and antibody fragments having high potency in neutralizing hCMV, wherein said antibodies and antibody fragments are specific for a combination of hCMV proteins UL130 and UL131A, or for a combination of hCMV proteins UL128... | 03/26/2009 |
| 20090074719 | Peptides, Peptidomimetics and Small Molecule Inhibitors of the Epstein-Barr Virus Mediated Fusion and Entry Process Disclosed are compositions and methods for modulating Epstein-Barr virus (EBV) infection in a patient. The compositions may include peptides or peptidomimetics that are related to gp42 and function to inhibit EBV-mediated membrane fusion.... | 03/19/2009 |
| 20090043280 | Vaccine Delivery Service The present invention relates to novel methods of vaccination and vaccine delivery. In particular, the invention relates to methods of vaccination and pre-filled vaccine delivery devices designed to deliver the vaccine into the dermis of an individual... | 02/12/2009 |
| 20090010964 | Lipid and Nitrous Oxide Combination as Adjuvant for the Enhancement of the Efficacy of Vaccines The invention provides for a method of enhancing immunological responses to an antigen in a vaccine formulation, and for a vaccine formulation that provides for an enhanced immunological response to an antigen. In the method and formulation the antigen is administered w... | 01/08/2009 |
| 20080311156 | VACCINES The present invention relates to adjuvant compositions which are suitable to be used in vaccines. In particular, the adjuvant compositions of the present invention comprises a saponin and an immunostimulatory oligonucleotide, optionally with a carrier. Also provided by ... | 12/18/2008 |
| 20080279886 | Safer Attenuated Virus Vaccines With Missing Or Diminished Latency Of Infection Viruses having weakened ability to establish and/or maintain latency and their use as live vaccines are described. The vaccines have one or more alterations in genes that provide continued virus replication but that inhibit latency. The vaccine materials and methods for... | 11/13/2008 |
| 20080279926 | Vaccine Compositions Comprising a Saponin Adjuvant An immunogenic composition in a dose volume suitable for human use comprising an antigen or antigenic preparation, in combination with an adjuvant which adjuvant comprises an immunologically active saponin fraction derived from the bark of Quillaja Saponaria Moli... | 11/13/2008 |
| 20080187545 | Cytomegalovirus surface protein complex for use in vaccines and as a drug target Immunogenic compositions and prophylactic or therapeutic vaccines for use in protecting and treating against human cytomegalovirus (CMV) are disclosed. Subunit vaccines comprising a human CMV protein complex comprising pUL128 or pUL130, and nucleic acid vaccines compris... | 08/07/2008 |
| 20080171002 | Products For Receptor Mediated Activation And Maturation Of Monocyte-Derived Dendritic Cells By A Phosphorylated Glucomannane Polysaccharide Phosphorylated glucomannan polysaccharide compositions are shown to effectively enhance healthy immune function. Dosage forms including pills, sprays, functional foods and cosmetics may achieve this benefit while being essentially free of storage protein from nongermina... | 07/17/2008 |
